Barinthus Biotherapeutics Statistics
Total Valuation
BRNS has a market cap or net worth of $91.54 million. The enterprise value is -$25.63 million.
| Market Cap | 91.54M |
| Enterprise Value | -25.63M |
Important Dates
The last earnings date was Monday, May 13, 2024, before market open.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BRNS has 38.95 million shares outstanding.
| Shares Outstanding | 38.95M |
| Owned by Insiders (%) | 3.69% |
| Owned by Institutions (%) | 47.85% |
| Float | 27.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 274.07 |
| Forward PS | n/a |
| PB Ratio | 0.53 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.15, with a Debt / Equity ratio of 0.07.
| Current Ratio | 11.15 |
| Quick Ratio | n/a |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,831.85 |
Financial Efficiency
Return on equity (ROE) is -36.70% and return on invested capital (ROIC) is -42.97%.
| Return on Equity (ROE) | -36.70% |
| Return on Assets (ROA) | -31.80% |
| Return on Capital (ROIC) | -42.97% |
| Revenue Per Employee | $2,569 |
| Profits Per Employee | -$543,985 |
| Employee Count | 130 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.26% in the last 52 weeks. The beta is -0.44, so BRNS's price volatility has been lower than the market average.
| Beta (1Y) | -0.44 |
| 52-Week Price Change | -1.26% |
| 50-Day Moving Average | 2.56 |
| 200-Day Moving Average | 2.81 |
| Relative Strength Index (RSI) | 47.02 |
| Average Volume (30 Days) | 24,053 |
Short Selling Information
| Short Interest | 19,022 |
| Short Previous Month | 14,111 |
| Short % of Shares Out | 0.08% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.52 |
Income Statement
In the last 12 months, BRNS had revenue of $334,000 and -$70.72 million in losses. Loss per share was -$1.84.
| Revenue | 334,000 |
| Gross Profit | 334,000 |
| Operating Income | -79.34M |
| Pretax Income | -73.31M |
| Net Income | -70.72M |
| EBITDA | -66.23M |
| EBIT | -73.27M |
| Loss Per Share | -$1.84 |
Balance Sheet
The company has $129.97 million in cash and $12.81 million in debt, giving a net cash position of $117.17 million or $3.01 per share.
| Cash & Cash Equivalents | 129.97M |
| Total Debt | 12.81M |
| Net Cash | 117.17M |
| Net Cash Per Share | $3.01 |
| Equity / Book Value | 171.83M |
| Book Value Per Share | 4.41 |
| Working Capital | 130.30M |
Cash Flow
In the last 12 months, operating cash flow was -$59.57 million and capital expenditures -$3.21 million, giving a free cash flow of -$62.79 million.
| Operating Cash Flow | -59.57M |
| Capital Expenditures | -3.21M |
| Free Cash Flow | -62.79M |
| FCF Per Share | -$1.62 |
Margins
Gross margin is 100.00%, with operating and profit margins of -23,755.69% and -21,173.05%.
| Gross Margin | 100.00% |
| Operating Margin | -23,755.69% |
| Pretax Margin | -21,950.30% |
| Profit Margin | -21,173.05% |
| EBITDA Margin | -19,828.74% |
| EBIT Margin | -21,938.32% |
| FCF Margin | -18,798.50% |
Dividends & Yields
BRNS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.00% |
| Shareholder Yield | -2.00% |
| Earnings Yield | -77.25% |
| FCF Yield | -68.59% |
Analyst Forecast
The average price target for BRNS is $8.00, which is 240.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 240.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 12.69% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BRNS has an Altman Z-Score of 0.22 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.22 |
| Piotroski F-Score | 2 |